Vince Sliwoski

Vince is an award-winning business lawyer, problem solver and dealmaker. His clients run the gamut from individual investors and entrepreneurs to widely held domestic and international corporations. Based in Portland, Oregon, he is Managing Partner of Harris Bricken and Editor of the Canna Law Blog.

oregon psilocybin service provider

Oregon Psilocybin Business Issues: Part 4

Welcome to the fourth installment in this series surveying business and regulatory issues in the Oregon psilocybin program. Today I’ll cover access to professional service providers. Service providers and the Oregon psilocybin industry I’ve mentioned before that Oregon psilocybin shares many parallels with what came before with cannabis. In the early days of cannabis, it

microdosing at work

Microdosing at Work

This article was originally published on Bill of Health, the blog of Petrie-Flom Center at Harvard Law School, as part of a digital symposium, A Macro View of Microdosing. In light of the widespread cultural and business culture adoption of microdosing, private sector employers should reconsider the implications of a blanket prohibition on workplace use of controlled substances. Microdosing

psilocybin testing rules

Oregon Psilocybin: Draft Testing Rules

Measure 109 covered psilocybin testing standards in some detail. It also directed the Oregon Health Authority (OHA) to adopt rules on this topic. I’ll cover the unreleased, first draft of those rules today. They begin at OAR 333-333-7010. As I wrote in parts one and two of this series (training; products) it’s important to remember that

oha rules psilocybin products

Oregon Psilocybin: Draft Products Rules

Oregon’s Measure 109 left much to do with “psilocybin products” to the administrative rulemaking process. Measure 109 defined “psilocybin products” as: “(A) psilocybin-producing fungi and (B) mixtures of substances containing a detectable amount of psilocybin.” Pretty simple. Beyond that, the measure directed the Oregon Health Authority to “establish a regulatory framework concerning psilocybin products.” This

oregon psilocybin training

Oregon Psilocybin: Draft Training Program Rules

The rules on Oregon psilocybin training programs, products and testing will be critical to the success of Measure 109. Last month, I advised that interested parties could look for these administrative rules sometime in May of 2022. The first known drafts, dated December 17, 2021, have been in our possession for a while, however, and

oregon psilocybin employment insurance real estate

Oregon Psilocybin: Business Issues, Part 3

Welcome to the third installment of this series surveying business and regulatory issues in the Oregon psilocybin program. Today I’ll cover real estate, insurance and employment issues. Real estate issues for Oregon psilocybin businesses Real estate is one of the areas where psilocybin will be fairly analogous to cannabis, with some wrinkles. Leasing property for

oregon psilocybin business

Oregon Psilocybin: Business Issues, Part 2

Welcome to the second installment in this series surveying business and regulatory issues for Oregon psilocybin program players. In part one, I covered the general process and schedule of Oregon Health Authority (OHA) rulemaking, by and through the Oregon Psilocybin Advisory Board. I also covered residency requirements, further restrictions on ownership, and taxation issues. In

oregon psilocybin business

Oregon Psilocybin: Business Issues

We’ve been taking early calls on Oregon psilocybin for over a year, going back to when Measure 109 passed. I’m always happy to talk to people, but there simply isn’t much to do yet. Currently, the Oregon Psilocybin Advisory Board (“Board”) and its subcommittees are meeting to formulate recommendations on program rules. Eventually draft rules

psilocybin therapy compass comp360

Is Psilocybin Really a Miracle Drug? Compass Pathways Releases Phase 2B Trial Results

Something strange happened yesterday. Psychedelics unicorn Compass Pathways released data for the largest clinical trial ever conducted of a psilocybin drug. Not only did the drug seem to work, but the heavily anticipated data were “breathtaking” in the words of Compass’ CEO. Immediately, the company’s publicly traded shares dropped 16%. Including the day prior, it